Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call Transcript Summary
Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call Transcript Summary
Third quarter Adjusted EBITDA was reported as a loss of $193,000, compared to a positive $458,000 in the same period of 2023.The following is a summary of the Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call Transcript:
以下是xtant medical控股公司（XTNT）2024年第三季度業績會議呼叫記錄摘要：
Financial Performance:
財務表現：
Xtant Medical Holdings reported a Q3 2024 revenue of $27.9 million, indicating a 12% year-over-year increase.
The company reaffirmed its full-year revenue guidance for 2024 between $116 to $120 million, reflecting an approximate total annual growth of 27% to 31% compared to 2023.
Third quarter Adjusted EBITDA was reported as a loss of $193,000, compared to a positive $458,000 in the same period of 2023.
Gross margin for Q3 2024 slightly decreased due to scale-related issues and stood at 58.4%.
Net loss for Q3 2024 was $5 million, compared to a net income of $9.2 million in Q3 2023, primarily due to lack of gains that were present in the previous fiscal year.
xtant medical控股公司報告了2024年第三季度營業收入爲2790萬美元，同比增長12%。
公司重申了2024年全年營業收入指導在116到12000萬美元之間，相較於2023年，預計年總增長率爲27%至31%。
第三季度調整後的EBITDA報告顯示虧損193,000美元，而2023年同期爲正458,000美元。
2024年第三季度毛利率由於規模相關問題略有下降，爲58.4%。
2024年第三季度淨虧損爲500萬美元，而2023年第三季度淨利潤爲920萬美元，主要是因爲缺少上一財年的收益。
Business Progress:
業務進展：
Successfully launched two new products: OsteoVive Plus and Cortera, after overcoming initial challenges.
Signed a licensing agreement with a major player in the wound care market, expected to generate minimum royalty revenues of $3.75 million in 2025.
Implemented operational enhancements and product manufacturing in-house, which aims to increase profitability and reduce dependency on external manufacturers.
Expansion and integration of the product range following the Surgalign acquisition, notably in hardware segments such as spinal implants.
成功克服最初的挑戰後，成功推出了兩款新產品：OsteoVive Plus和Cortera。
與傷口護理市場的主要參與者簽訂了許可協議，預計將在2025年產生至少375萬美元的版稅收入。
實施了內部運營改進和產品與製造，旨在提高盈利能力並減少對外部製造商的依賴。
在Surgalign收購後，擴大和整合產品範圍，尤其是在硬件領域，如脊椎植入物。
Opportunities:
機會：
The shift to internal manufacturing of biologics to gain better control over supply chain and increase production margins.
Expansion into the Orthobiologics sector with a complete product line and new growth opportunities in OEM sales which do not carry sales and marketing expenses.
轉向內部生產生物製品，以更好地控制供應鏈並提高生產利潤。
進軍骨科生物製品領域，擁有完整的產品線，並在OEm銷售方面開拓新的增長機會，不承擔銷售和營銷費用。
Risks:
風險：
Experienced softer sales than expected due to delays in product launches and a reduction in surgical procedures which impacted revenue streams.
Potential disruptions in the healthcare sector affecting procedural volumes, as seen in the seasonal reductions during summer months.
由於產品推出延遲和手術程序減少導致銷售額低於預期。
潛在的醫療保健板塊中可能會影響手術量，如夏季月份的季節性減少。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
